AIMC Topic: Glucagon-Like Peptide-1 Receptor Agonists

Clear Filters Showing 1 to 3 of 3 articles

Artificial intelligence in anti-obesity drug discovery: unlocking next-generation therapeutics.

Drug discovery today Mar 17, 2025
Obesity, a multifactorial disease linked to severe health risks, requires innovative treatments beyond lifestyle changes and current medications. Existing anti-obesity drugs face limitations regarding efficacy, side effects, weight regain and high co...
Humans Artificial Intelligence Animals Drug Discovery Obesity Anti-Obesity Agents Glucagon-Like Peptide-1 Receptor Agonists
View on PubMed DOI

Machine-Learning-Guided Peptide Drug Discovery: Development of GLP-1 Receptor Agonists with Improved Drug Properties.

Journal of medicinal chemistry Jul 8, 2024
Peptide-based drug discovery has surged with the development of peptide hormone-derived analogs for the treatment of diabetes and obesity. Machine learning (ML)-enabled quantitative structure-activity relationship (QSAR) approaches have shown great p...
Humans Machine Learning Animals Male Peptides Drug Discovery Mice Mice, Inbred C57BL Obesity Quantitative Structure-Activity Relationship Mice, Obese Glucagon-Like Peptide-1 Receptor Agonists
View on PubMed DOI

Machine learning designs new GCGR/GLP-1R dual agonists with enhanced biological potency.

Nature chemistry May 16, 2024
Several peptide dual agonists of the human glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R) are in development for the treatment of type 2 diabetes, obesity and their associated complications. Candidates must have high poten...
Humans Machine Learning Peptides Drug Design Hypoglycemic Agents Amino Acid Sequence Glucagon-Like Peptide-1 Receptor Receptors, Glucagon Glucagon-Like Peptide-1 Receptor Agonists
View on PubMed DOI
Popular Topics
Recent Journals